The National Health Authority (NHA) on Thursday invited comments on the consultation paper for Drug Registry Application, which the authority intends to develop as a centralised repository of all approved drugs available in the market. The consultation paper has been released by NHA. “The consultation paper focuses only on Drug Registry within the National Digital Health Ecosystem and offers NHA’s current vision on the functionalities of the proposed Drug Registry, the process for its creation and potential benefits to various ecosystem stakeholders. Each section has specific open questions where feedback from stakeholders is sought,” NHA said in a statement here. The authority also said that comments from the public are invited to ensure that Drug Registry is designed and developed in a collaborative and consultative manner. NHA CEO RS Sharma urged all the stakeholders to provide their feedback on the consultation paper. He said, “Through Drug Registry, Ayushman Bharat Digital Mission (ABDM) aims to provide a standardised, comprehensive set of verified data on all the approved drugs marketed in the country that would enable a more efficient regulatory process. “To enable inclusivity and widen the perspectives on the table, I urge all stakeholders to go through the shared consultation papers and provide us with their valuable feedback,” he added. Envisioned under the ambitious Ayushman Bharat Digital Mission (ABDM), Drug Registry is intended to be a single, up-to-date, centralized repository of all the drugs across all systems of medicine that are approved and are available in the Indian Market. The Drug Registry application has been proposed to be designed using open-source technologies and will be interoperable, said the statement.